# SS-31 + MOTS-c Protocol: Mito Peptide Stack with NAD+

## SS-31 and MOTS-c with NAD+: A Protocol for Energy Restoration

Difficult-to-explain chronic fatigue is becoming more common. Long COVID, GLP-1-driven weight loss with sustained caloric deficits, and persistent oxidative stress converge on an energy-production bottleneck. Under-fueling, thyroid drag, inflammation, poor sleep, post-viral stress, GLP-1 titration, and overtraining can create the same pattern: chronic fatigue, metabolic inflexibility, and slow recovery when cells cannot turn fuel into usable ATP fast enough.

The Mitochondrial Peptide Stack is an 8–12+ week [SS-31](/content/ss-31), [MOTS-c](/content/mots-c), and [NAD+](/content/nad-guide) protocol built for that bottleneck. SS-31 begins first with NAD+ running as support; MOTS-c enters in week 2 to build capacity on a steadier foundation.

The practical case for the protocol is strongest in people experiencing GLP-1 fatigue, where rapid caloric deficit from [semaglutide](/content/semaglutide), [tirzepatide](/content/tirzepatide), or [retatrutide](/content/retatrutide) can strain energy capacity. Retatrutide adds a measured hepatic-fat-oxidation signal; using this stack to correct the downstream fatigue remains the protocol synthesis.¹² ¹³

[Jump to protocol](#protocol-12-week-mito-stack-cycle) | [Where to buy →](#where-to-buy-ss-31-mots-c-and-nad)

## At a Glance

| | |
| --- | --- |
| **Protocol** | An 8–12+ week course.<br>SS-31 begins first; MOTS-c enters in week 2; NAD+ runs throughout. After week 8, SS-31 stays daily while the response is building or moves to 2–3× per week once stable. |
| **Dosage** | SS-31: 6 mg daily through week 8, then 6 mg daily or 2–3× per week.<br>MOTS-c: 5–10 mg 2–3× per week from week 2.<br>NAD+: 100–200 mg IM 2–3× per week -> taper to 100–250 mg total weekly. |
| **Results timeline** | The protocol is designed for gradual energy restoration rather than stimulation; a sudden jolt of energy is not expected.<br>SS-31's slower structural response builds across weeks 4–8. Human mitochondrial-dysfunction data show continued improvement between weeks 12 and 24 before flattening.² |
| **Side effects** | All three compounds can cause injection-site reactions, including irritation, bruising, or welts. FoxAI suggests BAC water with NaCl for SS-31 and MOTS-c because it matches tissue tonicity, and pre-buffered NAD+ because NaCl does not correct its acidity.<br>Temporary fatigue can occur early in the daily SS-31 phase. NAD+ can cause flushing, nausea, dizziness, or chest-pressure sensations when administered too quickly. |
| **Regulatory status** | Elamipretide is FDA-approved narrowly for Barth syndrome; this three-compound protocol is not FDA-approved.<br>MOTS-c and injectable NAD+ are not FDA-approved for energy or metabolic indications. |
| **Best stacked with** | [Semaglutide](/content/semaglutide), [Tirzepatide](/content/tirzepatide), or [Retatrutide](/content/retatrutide) when GLP-1 energy drag is the use case.<br>[L-Carnitine injectable](/content/l-carnitine) for fatty acid transport support. |

---

## What Is a Mitochondrial Peptide Stack?

The stack combines three compounds because mitochondrial output depends on three layers: structure, signaling, and redox support. These determine whether mitochondria can keep up with the work being asked of them.

SS-31 protects the inner membrane where energy is made, the part that degrades with age, inflammation, and oxidative stress (cardiolipin binding). MOTS-c is part of the body's exercise-response system: mitochondria release it during physical stress, telling cells to build more capacity and shift how they use energy (AMPK activation). NAD+ supplies the redox currency both processes spend, and its availability declines with age and chronic inflammatory load.

## Evidence Status

FoxAI developed the Mito Stack Protocol by combining the available evidence for each component with endogenous physiology, published protocols, and mechanistic systems-biology. The complete three-component stack has not been tested in a randomized trial.¹¹

| Evidence layer | What supports this protocol |
| --- | --- |
| **Direct human evidence** | SS-31 has human mitochondrial-disease trials. NAD+ biology and precursor interventions have human data. No human trial has tested SS-31 + MOTS-c + NAD+ together. |
| **Human physiology and adjacent evidence** | Native MOTS-c has animal and human exercise-physiology data; that does not make an engineered MOTS-c analog or the complete stack clinically interchangeable. |
| **Mechanistic inference** | Membrane stabilization, adaptive signaling, and redox support target distinct parts of mitochondrial energy production. |
| **Protocol reports** | User reports, especially from researchers over 40 and those experiencing heightened fatigue during GLP-1 weight-loss therapy, describe meaningful energy restoration and support the phased sequence. Some users also report pronounced fatigue around days 3–5 of the opening daily SS-31 phase. [See user reports](#real-world-evidence-user-reports). |
| **Protocol synthesis** | The 8–12+ week sequence and cadence come from FoxAI synthesis and the component evidence, not a randomized combination trial. |

## The Three Axes of Mitochondrial Health

| Axis                               | Function                           | How It Fails                           | Result                                  |
| ---------------------------------- | ---------------------------------- | -------------------------------------- | --------------------------------------- |
| Inner membrane structure (cardiolipin) | Holds the energy-producing chain in place | Oxidized membranes leak electrons | Low ATP, more oxidative waste, inflammation |
| Redox currency (NAD+) | Powers energy production and activates repair enzymes (sirtuins) | Depleted by stress, aging, alcohol | Fatigue, DNA damage, metabolic rigidity |
| Adaptation signal (AMPK → PGC-1α) | Tells cells to build more mitochondria | Blunted by cortisol, nutrient overload | Slow recovery, weight gain |

---
## Component 1: SS-31 — Membrane Repair

Every mitochondrion has an inner membrane where energy production happens. That membrane depends on a specific molecule — cardiolipin — to hold the energy-producing machinery in place. As cardiolipin degrades from age and oxidative stress, the machinery loosens. Energy output drops. Waste products (reactive oxygen species) spike. The mitochondrion starts costing more to run than it produces.

SS-31 (also called elamipretide) stabilizes cardiolipin directly — tightening the energy-producing chain so it runs cleanly instead of leaking. The best fit is a system where that membrane is already stressed: aging, post-viral fatigue, overtraining, metabolic stress, or a known mitochondrial condition. When mitochondria are already young and healthy, there may be less damaged membrane for SS-31 to protect.¹

SS-31 has the deepest human trial record of the mitochondrial peptides covered here. Its FDA approval is narrow: Barth syndrome, based on an accelerated-approval package that included a randomized TAZPOWER crossover that missed both primary endpoints and a longer open-label extension that reported sustained functional and cardiac changes. MMPOWER-3 in primary mitochondrial myopathy also missed its primary endpoint, with subgroup signals that remain specific to that disease cohort.²

See [SS-31 guide](/content/ss-31) for complete coverage.

---

## Component 2: MOTS-c — Metabolic Reprogramming

The body already makes MOTS-c — mitochondria release it during exercise. It is the signal that tells cells to adapt: build more mitochondria, get better at burning fat, and handle glucose more efficiently. Exercise raises plasma MOTS-c about 1.5–1.6-fold, while levels measured in skeletal muscle rise about 11.9-fold.⁴

Where SS-31 protects existing mitochondria, MOTS-c tells cells to build more capacity. It triggers the same cellular response endurance training does through AMPK signaling, helping cells build new mitochondria and shift toward more flexible fuel use. This is why MOTS-c fits training plateaus, GLP-1 fatigue, post-viral drag, and metabolic-flexibility work.³

Native MOTS-c human outcome data is still developing. The strongest current anchors are the original *Cell Metabolism* discovery work, human exercise physiology, and the completed Phase 1 registration for CB4211, an engineered analog whose public registry record has no posted results. Native MOTS-c and CB4211 are not interchangeable; the analog trial supplies adjacent safety-class context, not native-peptide outcome data.⁵

See [MOTS-c guide](/content/mots-c) for more.

---

## Component 3: NAD+ — Cellular Fuel

NAD+ is the redox currency cells spend to make energy, repair damage, regulate inflammation, and maintain circadian timing. Its availability declines with age and can fall faster under chronic stress and inflammation. When the pool is low, the same mitochondrial signal can land poorly because the cell lacks the currency to act on it.⁶

Restoring NAD+ does not create energy out of nothing. It removes a bottleneck: cells can turn fuel into ATP more efficiently, fund repair work, and tolerate training or deficit pressure with less crash.

Oral precursors like NR and NMN are legitimate tools for daily pool support. Injectable NAD+ is mostly broken down outside cells into usable precursors and creates a stronger pulsed exposure.⁷ FoxAI protocols often prefer IM for active rebuilds; SubQ runs 50–100 mg per dose, split into injections of 50 mg or less, when irritation is managed; above 100 mg use IM.

The injectable routes picked up their first controlled human data in 2026: a small double-blind trial (45 people, nine arms) gave 100 mg NAD+ by IM, IV, and SC across three days and found all three tolerated. That covers the lower end of the dose used here. It does not cover delivery: the trial held back its blood-NAD+ measurement, so how much reaches tissue by IM or SC is still open, and the 200 mg end of this range remains practice-derived.

See [NAD+ Guide](/content/nad-guide) for a deep dive.

---

## MOTS-c and SS-31: How They Work Together

MOTS-c and SS-31 both target mitochondria, but they do different jobs. MOTS-c is the adaptation signal. SS-31 is the structural support.

| Feature | MOTS-c | SS-31 (Elamipretide) |
| :--- | :--- | :--- |
| **Origin** | Natural (Mitochondrial DNA) | Synthetic |
| **Main Target** | AMPK Pathway / Nucleus | Cardiolipin / Inner Membrane |
| **Best For** | Metabolism, Fat Loss, Endurance | Recovery, Organ Health, Repair |
| **Plain role** | Expansion signal | Membrane protection |

### Why Combine MOTS-c and SS-31?
SS-31 is used to stabilize existing mitochondria that are struggling, reducing electron leak and oxidative stress. Once the structure is steadier, MOTS-c is used to signal for more capacity and better fuel flexibility.

Together, they cover two different bottlenecks: SS-31 protects the machinery, while MOTS-c tells the system to adapt. NAD+ is added because both processes spend redox currency.

When ATP production clears the cell's maintenance demand, more energy becomes available for downstream repair. FoxAI uses that threshold to explain the reported shift from "managing decline" to recovering more consistently; timing and magnitude vary.

---

## 8–12+ Week Mito Stack Protocol {#protocol-12-week-mito-stack-cycle}

Standard course: 8–12+ weeks. SS-31 runs daily through week 8; after that, continue daily while the response is still building or move to 2–3× weekly once stable. Maintenance protocols pulse MOTS-c alongside NAD+ at 100–250 mg total weekly.¹¹

MOTS-c enters in week 2 once the opening SS-31 response is stable. If pronounced fatigue or local reactions persist, the start moves to week 3.


| Phase               | SS-31                                | MOTS-c            | NAD+                    |
| ------------------- | ------------------------------------ | ----------------- | ----------------------- |
| Week 1              | 6 mg daily                           | n/a               | 100–200 mg IM 2–3×/week |
| Weeks 2–8           | 6 mg daily                           | 5–10 mg 2–3×/week | 100–200 mg IM 2–3×/week |
| Weeks 9–12+         | 6 mg daily or 2–3×/week              | 5–10 mg 2–3×/week | 50–100 mg IM 1–3×/week  |

**Critical Support**: daily electrolytes and zone-2 cardio early on, resistance training and protein ≥1.6 g/kg through the build phase, and glycine + collagen layered in as repair support.

### Why each compound is scheduled the way it is

The three components are on the calendar for three different reasons, and knowing which is which tells you what to do when the stack underdelivers.

| Compound | What governs its schedule | If it seems not to be working |
| --- | --- | --- |
| SS-31 | Course length. The structural effect takes 4–8 weeks to appear, and human improvement continued between weeks 12 and 24 before flattening.² | Dose daily through week 8. Then stay daily while response is building or move to 2–3× weekly once stable. |
| MOTS-c | Coupling to load. The signal clears within a day; what it drives accrues over weeks, so each dose needs a demand to act on. | Check whether doses land near training. Through a deload or sedentary stretch, pause rather than keep the calendar. |
| NAD+ | Consistency. The pool drifts back during gaps regardless of what else is running. | Check missed days before raising the dose. |

**The practical upshot: raising the dose is the wrong first move for two of the three.** SS-31 needs time, MOTS-c needs a demand, and only NAD+ responds to a supply question — and even there, consistency usually beats a bigger number.

This scheduling logic is read off mechanism and animal time-course work, not from a trial comparing schedules. No such trial exists for any of the three.

### Timeline of Effects

This is the expected FoxAI sequence, not a trial-measured timeline.

| Timeframe  | Expected biological sequence           | Reported effects                             |
| ---------- | -------------------------------------- | -------------------------------------------- |
| Weeks 1–2  | SS-31 begins membrane engagement       | Warm steady energy, less soreness — this is the fast, reversible phase, not the structural one |
| Weeks 3–4  | MOTS-c begins adaptive signaling       | Cardio feels easier, cravings decrease       |
| Weeks 5–8  | SS-31's structural phase arrives; NAD+ supports redox-dependent repair | Better sleep, clearer skin, mental sharpness |
| Weeks 9–12+ | SS-31 continues building or shifts to maintenance cadence | Resilience under stress, faster recovery     |

---
## Where to buy SS-31, MOTS-c, and NAD+
Please read through PeptideFox's [sourcing guide](/sourcing). Our stance is toward quality, safety, and accountability — therefore, we advise against social-media based sourcing and direct import through Chinese vendors.

SS-31, which is FDA approved as Forzinity, is difficult to source without a prescription and we are unable to provide guidance on a reliable research-use-only source.

MOTS-c is available through Research Use Only vendors. For NAD+, as noted, a pre-buffered version is strongly advised.

As of July 2026, we have one fully vetted vendor — [Aminos Research](https://aminosresearch.com/ruo) — that meets all of our criteria, namely U.S. manufactured (operations directly verified by PeptideFox) with a fully clean 3rd party testing profile (i.e. no anomolies, missing reports, invalidated links). We will continue to assess additional vendors in the coming months.

[Buy MOTS-c](https://aminosresearch.com/product/mots-c/ref/10/) | [Buy Buffered NAD+](https://aminosresearch.com/product/nad-buffered/ref/10/)

---

## Real-World-Evidence: User Reports

> <!-- rwe-stage: SS-31 loading · days 3–4 -->
> My [research subject] is on week 10 of the Mito Stack from peptidefox.com. Subject is 55M and was definitely in need of repair, starting with the inside and felt SS31 had to do a lot of work during the loading phase (8 days/10mg) as evidenced by fatigue on day 3 and 4.
>
> <!-- rwe-stage: MOTS-c introduced · week 2 -->
> Once MOTS-c was introduced in week 2, [research subject] felt amazing and is now alternating days of SS31/ MOTS-c with Sunday off — also on Reta, NAD+ and Tesa. This stack has helped [research subject] bloodwork improve across the board.
>
> <!-- rwe-stage: Assessment · week 10 -->
> All said, RS is in agreement that over 40 should do SS31 for even a short period before MOTS-c to allow MOTS-c to do what it does best. Check out the site and the stack, it's worth investigating at minimum.
[u/cnat721 — posted June 2026](https://www.reddit.com/r/Biohacking/comments/1uhleht/comment/oucw4i9/)

> <!-- rwe-stage: Current protocol · week 2 -->
> I'm currently following this protocol: https://peptidefox.com/content/mito-stack-protocol
>
> <!-- rwe-stage: Dose context -->
> Albeit on the lower end of the recommended doses. Currently in week 2.
>
> <!-- rwe-stage: Week 1 -->
> Week 1 was daily 5mg of SS31 with 50mg of NAD+ Tuesday/Thursday/Sunday.
>
> <!-- rwe-stage: Week 2 -->
> Week 2 is 7.5mg SS31 daily with same NAD+ (NAD+ doses are smaller than protocol as that suggests IM and I pin SubQ)
>
> <!-- rwe-stage: Next step · week 3 -->
> So far so good. No fatigue and looking forward to adding MOTS-C next week.
[u/Stoo84 — posted May 2026](https://www.reddit.com/r/Biohacking/comments/1tmenja/comment/onm5ok0/)


---

## How to Reconstitute SS-31, MOTS-c, and NAD+ to Avoid Injection Site Reactions

Both SS-31 and MOTS-c can be injection-site-reactive in protocol use. SS-31 has direct MRGPRX2 mast-cell evidence; for MOTS-c, that mechanism is an inference from its cationic profile and field reaction pattern. FoxAI therefore suggests reconstituting with bacteriostatic 0.9% sodium chloride. The reason is tonicity: plain BAC water is hypotonic, and a hypotonic bolus irritates tissue on its own, while saline matches the fluid it lands in.⁸,¹⁰

No controlled study has compared these diluents for either peptide. This is FoxAI's formulation synthesis supported by chemistry and repeated field observation.

NAD+ requires a two-step fix. Many reconstituted NAD+ products land around pH 3–4 — highly acidic, which is what causes the burning and/or stinging senstation. NaCl can improve tonicity but cannot raise pH. It is suggested to source NAD+ pre-buffered — which means the pH level has been raised; slower administration, greater dilution, and IM administration can further reduce local burn.⁹

The protocol keeps each compound in a separate vial and syringe. Salt or bicarbonate is never added manually. Sodium chloride can shorten stability in some peptide formulations by increasing aggregation risk. The conservative default is to use a smaller vial, and consume it within 1–2 weeks unless the manufacturer or dispensing pharmacy specifies a different beyond-use date.¹⁰

Need help preparing your peptides? See Peptide Fox's [Reconstitution Guide](/content/reconstitution) for step-by-step instructions.

---


## Applications

### GLP-1 Fatigue: The Mitochondrial Bottleneck

Fatigue is a recurring adverse event in semaglutide trials and a recurring complaint in FoxAI GLP-1 protocol use. Semaglutide fatigue, tirzepatide fatigue, Ozempic fatigue, and Mounjaro fatigue describe that field pattern rather than one proven mechanism across every drug. Energy can drop during titration or after months of sustained deficit even when weight loss is proceeding.¹²

**Why it happens:** GLP-1 agonists can lower intake quickly and shift more work toward stored fuel. Retatrutide adds a directly measured hepatic-fat-oxidation signal. If the user is under-eating protein, low on electrolytes, sleeping poorly, pushing titration too fast, or already carrying inflammation or thyroid drag, the bottleneck can land in energy production.¹³

**Why the Mito Stack helps:** The stack addresses all three failure points:

- **SS-31** repairs the membrane structure so electrons flow cleanly (less waste, more output)
- **MOTS-c** signals cells to build more mitochondria and improve fuel selection (more capacity)
- **NAD+** provides the redox currency both processes require (fuel for the machinery)

The goal is simple: help mitochondria execute the fuel shift GLP-1s are creating. That does not replace food, protein, sleep, thyroid assessment, or slower titration. It supports the layer underneath them.

**Practical integration:** Many users start with NAD+ support first, especially during active titration or a hard caloric deficit. MOTS-c fits when training tolerance, post-exertional fatigue, or metabolic flexibility is the issue. SS-31 is the escalation layer when recovery from exertion remains slow or the fatigue pattern looks more structural than simply under-fueled.

For a complete breakdown of why each GLP-1 compound causes different types of fatigue — and the full intervention hierarchy from protein to mitochondrial support — see [Why GLP-1 Medications Make You Tired](/content/glp1-fatigue). For retatrutide-specific NAD+ implementation, see the [Retatrutide + NAD+ Protocol](/content/retatrutide-nad-protocol).

### Injury recovery

The Mito-Stack provides the ATP foundation that tissue repair requires. In injury protocols, NAD+ can start early as the energy layer; SS-31 and MOTS-c become more relevant when fatigue, post-exertional drag, or mitochondrial recovery remains the limiter after vascular repair is underway. See our [injury recovery protocol](/content/injury-recovery-peptide-protocol) for more detail.

### Longevity and anti-aging

By sustaining sirtuin activity, supporting DNA repair, and maintaining mitochondrial density, the Mito-Stack addresses the metabolic decline that underlies aging.

---

## Side Effects and Safety

**SS-31:** FDA approved narrowly for Barth syndrome. Injection-site irritation, bruising, and induration are the main practical issues, especially at higher concentration or larger volume.²

**MOTS-c:** FoxAI protocol reports commonly describe injection-site reactions. Fatigue or a glucose-dip feeling can occur if dosing is too fasted, calories are too low, or the user is methylation-sensitive.

**NAD+:** Slow injection rates reduce flushing, nausea, dizziness, and chest-pressure sensations. IM is preferred for active rebuilds; SubQ runs 50–100 mg per dose, split into injections of 50 mg or less.⁷,⁹

**Contraindications:** Active malignancy, pregnancy or breastfeeding, acute infection or uncontrolled inflammation, and chemotherapy regimens that depend on NAD+ depletion.

**Cautions:** Severe renal impairment changes SS-31 exposure; the approved Barth regimen is reduced in severe kidney impairment rather than treated as a blanket contraindication. Heart failure, significant arrhythmia history, recent cardiac events, and uncontrolled hypertension are the profiles that warrant medical oversight. For methylation-sensitive users, MTHFR status is one modifier rather than a stand-alone rule; FoxAI protocols open lower when low B12 or folate status, headaches, anxiety, insomnia, or post-dose crash are also present.²

**Monitoring:** The standard panel is baseline and month-2 checks for CMP, lipids, and hs-CRP.

---

## FAQ

### What alternatives to injectable NAD+ are used in the Mito Stack?

The full stack logic depends on some form of NAD+ support, but it does not have to be injectable for every user. IM NAD+ is the preferred active-rebuild route. Oral NR or NMN can work as a steadier maintenance layer or for users who do not tolerate injections.

### How does The Mito Stack differ from NAD+ therapy alone?

NAD+ supports the redox pool, but it does not protect damaged mitochondrial membranes or send the adaptation signal to build more capacity. The full Mito Stack addresses structure, signaling, and substrate instead of leaning on substrate alone.

### Is the Mito Stack anabolic?

Not directly muscle-building, but by improving ATP production and reducing inflammation, it makes training and any growth-hormone protocol more effective.

### What dosing ranges are commonly described for the MOTS-c and SS-31 stack?

This protocol uses MOTS-c 5–10 mg SubQ 2–3 times weekly and SS-31 6 mg SubQ daily through week 8. After week 8, SS-31 continues daily while the response is still building or moves to 2–3 times weekly once stable. NAD+ commonly runs 100–200 mg IM 2–3 times weekly during active rebuilds, then lower for maintenance.

### Can you take SS-31 and MOTS-c together?

FoxAI protocols use a 4–6 hour gap or alternate days. SS-31 supports mitochondrial membrane structure, while MOTS-c drives the signal to build more capacity. Separating them stages those two jobs; no controlled interaction study has shown that same-time administration is harmful.

### How long should SS-31 be used before adding MOTS-c?

FoxAI's protocol uses SS-31 alone through week 1, then adds MOTS-c in week 2 once the opening response is stable. If pronounced fatigue or local reactions persist, the MOTS-c start moves to week 3. SS-31 itself remains daily through week 8.

---

## Related Topics

- [NAD+ Guide](/content/nad-guide): Complete NAD+ overview
- [SS-31 Guide](/content/ss-31): Elamipretide — Cardiolipin stabilizer at the core of the stack
- [MOTS-c Guide](/content/mots-c): Deep dive on MOTS-c
- [MOTS-c with NAD+ Stack](/content/nad-mots-c-stack): A lighter stack for energy when SS-31 is not needed 
- [Circadian Reset Protocol](/content/circadian-reset-protocol): How NAD+/MOTS-c support the circadian clock
- [Peptide Stacking Guide](/content/peptide-stacking-guide): How the Mito Stack fits into the 5-axis stacking framework
- [Retatrutide + NAD+ Protocol](/content/retatrutide-nad-protocol): GLP-1 with metabolic support
- [GLP-1 Fatigue](/content/glp1-fatigue) — Addressing the 3-6 month wall with the Mito Stack


---

## References

### SS-31

¹ Birk AV, et al. The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. _J Am Soc Nephrol_. 2013;24(8):1250-1261. [PMC3752943](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752943/)

² U.S. Food and Drug Administration. Forzinity integrated review: SPISC-101 healthy-adult PK at 6 mg daily for seven days, the elamipretide clinical program, injection-site reactions, renal dose adjustment, and Barth syndrome approval. 2025. [FDA integrated review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000IntegratedR.pdf)

### MOTS-c

³ Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. _Cell Metab_. 2015;21(3):443-454. [DOI: 10.1016/j.cmet.2015.02.009](https://doi.org/10.1016/j.cmet.2015.02.009)

⁴ Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. _Nat Commun_. 2021;12:470. [DOI: 10.1038/s41467-020-20790-0](https://doi.org/10.1038/s41467-020-20790-0)

⁵ CB4211 Phase 1a/1b registry record. The study tested an engineered MOTS-c analog; the public record does not post results. [ClinicalTrials.gov NCT03998514](https://clinicaltrials.gov/study/NCT03998514)

### NAD+

⁶ Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. _Nat Rev Mol Cell Biol_. 2021;22:119-141. [PMC7963035](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/)

⁷ Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+. _Front Aging Neurosci_. 2019;11:257. [PMC6751327](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/)

### Reconstitution and tolerability

⁸ Sullivan A, Bergheanu SC, Kropp LE, et al. Interventions with potential to mitigate injection-site reactions following subcutaneous elamipretide administration: a Phase 1 crossover study. _Arch Microbiol Immunol_. 2023;7:306-317. [Full text](https://www.fortunejournals.com/articles/interventions-with-potential-to-mitigate-injection-site-reactions-following-subcutaneous-elamipretide-administration-a-phase-1-cro.html)

⁹ St Clair-Jones A, et al. Understanding and minimizing injection-site pain following subcutaneous administration. _Rheumatol Ther_. 2020;7:741-757. [PMC7672413](https://pmc.ncbi.nlm.nih.gov/articles/PMC7672413/)

¹⁰ Ouberai MM, Dos Santos ALG, Kinna S, et al. Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly. _Nat Commun_. 2017;8:1026. [DOI: 10.1038/s41467-017-01114-1](https://doi.org/10.1038/s41467-017-01114-1)

### Protocol and GLP-1 context

¹¹ FoxAI protocol and formulation synthesis. The 8–12+ week sequence and reconstitution preferences combine per-compound physiology, formulation chemistry, published protocols, and observed use. No randomized trial has tested the complete stack, the same-time administration question, or the preferred diluents against one another.

¹² Sillassen L, et al. Safety of semaglutide: a systematic review and meta-analysis of 50 randomized trials. _BMC Med_. 2025. [PMC12642075](https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/)

¹³ Retatrutide hepatic oxidation — Sanyal AJ, et al. measured liver-fat and β-hydroxybutyrate changes: [10.1038/s41591-024-03018-2](https://doi.org/10.1038/s41591-024-03018-2). Pearson MJ, et al. measured the lipid and metabolite fingerprint: [10.1210/clinem/dgag201](https://doi.org/10.1210/clinem/dgag201). These establish Retatrutide's hepatic FAO demand; no trial has tested SS-31, MOTS-c, or injected NAD+ as the downstream fatigue intervention.